16-iodo-3-methylhexadecanoic acid has been researched along with Constriction, Pathologic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angioï, M; Bertrand, A; Cherrier, F; Danchin, N; Fagret, D; Grentzinger, A; Juillière, Y; Karcher, G; Marie, PY; Olivier, P; Virion, JM | 1 |
1 other study(ies) available for 16-iodo-3-methylhexadecanoic acid and Constriction, Pathologic
| Article | Year |
|---|---|
Assessment of myocardial viability in patients with previous myocardial infarction by using single-photon emission computed tomography with a new metabolic tracer: [123I]-16-iodo-3-methylhexadecanoic acid (MIHA). Comparison with the rest-reinjection thall
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Cell Survival; Constriction, Pathologic; Exercise Test; Female; Heart; Humans; Iodine Radioisotopes; Male; Middle Aged; Myocardial Contraction; Myocardial Infarction; Myocardium; Palmitic Acids; Prospective Studies; Thallium Radioisotopes; Tomography, Emission-Computed, Single-Photon | 1997 |